MA34977B1 - Composés à base de complexes de FE(III) pour le traitement et la prévention de carences en fer et d'anémies dues à une carence en fer. - Google Patents

Composés à base de complexes de FE(III) pour le traitement et la prévention de carences en fer et d'anémies dues à une carence en fer.

Info

Publication number
MA34977B1
MA34977B1 MA36272A MA36272A MA34977B1 MA 34977 B1 MA34977 B1 MA 34977B1 MA 36272 A MA36272 A MA 36272A MA 36272 A MA36272 A MA 36272A MA 34977 B1 MA34977 B1 MA 34977B1
Authority
MA
Morocco
Prior art keywords
iron deficiency
complexes
prevention
iii
treatment
Prior art date
Application number
MA36272A
Other languages
English (en)
Inventor
Thomas Bark
Wilm Buhr
Susanna Burckhardt
Michael Burgert
Camillo Canclini
Franz Dürrenberger
Felix Funk
Peter Otto Geisser
Aris Kalogerakis
Simona Mayer
Erik Philipp
Stefan Reim
Diana Sieber
Jörg Schmitt
Katrin Schwarz
Original Assignee
Vifor Int Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44140927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34977(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vifor Int Ag filed Critical Vifor Int Ag
Publication of MA34977B1 publication Critical patent/MA34977B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des composés à base de complexes de Fe(III) et des compositions pharmaceutiques les contenant, destinées à être utilisées comme médicaments, en particulier pour le traitement et/ou la prévention de carences en fer et d'anémies dues à une carence en fer.
MA36272A 2011-03-29 2012-03-28 Composés à base de complexes de FE(III) pour le traitement et la prévention de carences en fer et d'anémies dues à une carence en fer. MA34977B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11160151 2011-03-29
PCT/EP2012/055512 WO2012130882A1 (fr) 2011-03-29 2012-03-28 Composés à base de complexes de fe(iii) pour le traitement et la prévention de carences en fer et d'anémies dues à une carence en fer

Publications (1)

Publication Number Publication Date
MA34977B1 true MA34977B1 (fr) 2014-03-01

Family

ID=44140927

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36272A MA34977B1 (fr) 2011-03-29 2012-03-28 Composés à base de complexes de FE(III) pour le traitement et la prévention de carences en fer et d'anémies dues à une carence en fer.

Country Status (31)

Country Link
US (1) US9422247B2 (fr)
EP (1) EP2691376B1 (fr)
JP (1) JP5923161B2 (fr)
KR (1) KR101889050B1 (fr)
CN (1) CN103429575B (fr)
AR (1) AR085736A1 (fr)
AU (1) AU2012234292B2 (fr)
BR (1) BR112013024722B1 (fr)
CA (1) CA2829240C (fr)
CL (1) CL2013002766A1 (fr)
CO (1) CO6811850A2 (fr)
CR (1) CR20130485A (fr)
DK (1) DK2691376T3 (fr)
DO (1) DOP2013000213A (fr)
EA (1) EA026192B1 (fr)
EC (1) ECSP13012904A (fr)
ES (1) ES2560964T3 (fr)
GT (1) GT201300224A (fr)
HU (1) HUE026712T2 (fr)
IL (1) IL228502A (fr)
MA (1) MA34977B1 (fr)
MX (1) MX358194B (fr)
MY (1) MY168952A (fr)
PE (1) PE20141319A1 (fr)
PL (1) PL2691376T3 (fr)
PT (1) PT2691376E (fr)
SG (1) SG193981A1 (fr)
TN (1) TN2013000379A1 (fr)
TW (1) TWI510496B (fr)
WO (1) WO2012130882A1 (fr)
ZA (1) ZA201308050B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105246473B (zh) 2012-12-21 2018-07-13 维福（国际）股份有限公司 用于缺铁症状和缺铁性贫血的治疗和预防的Fe(III)络合化合物
CN103951552B (zh) * 2014-04-11 2015-09-30 浙江宏元药业有限公司 瑞舒伐他汀中间体及其制备方法
RU2625739C1 (ru) * 2016-09-28 2017-07-18 Общество с ограниченной ответственностью Научно-производственное предприятие "Эксорб" Фармакологическая композиция на основе соединений железа

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US474670A (en) 1892-05-10 Automatic fire-alarm
GB842637A (en) 1955-12-27 1960-07-27 Andre Georges Jules Jallais Glass frames, more especially for forced cultivation
GB2128998B (en) 1982-10-22 1986-07-16 Nat Res Dev Pharmaceutical compositions of iron complexes of 3 hydroxy-4-pyrone
GB8325496D0 (en) 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
US4788281A (en) 1984-01-04 1988-11-29 Tosoni Anthony L Dextran hexonic acid derivative, ferric hydroxide complex and method manufacture thereof
GB8410289D0 (en) 1984-04-19 1984-05-31 Callingham B A Pharmaceutical compositions
IT1222654B (it) 1987-09-14 1990-09-12 Schering Ag Complesso micellare di ferro-citrato
JPH0283400A (ja) 1988-09-21 1990-03-23 Snow Brand Milk Prod Co Ltd 鉄カゼインの製造方法
ES2044777B1 (es) 1992-03-03 1994-08-01 Dabeer Sa Procedimiento de obtencion de un quelato de hierro de gran solubilidad.
US20030236224A1 (en) 1997-12-09 2003-12-25 Hedlund Bo E. Modified polysaccharides exhibiting altered biological recognition
IT1297022B1 (it) 1997-12-24 1999-08-03 Chemi Spa Complesso di ferro-succinilcaseina, processo per la sua preparazione e composizioni farmaceutiche che lo contengono
DE10253843B3 (de) 2002-11-14 2004-05-06 Bizerba Gmbh & Co. Kg Etikettiervorrichtung für bewegte Gegenstände und Verfahren zur Etikettierung von bewegten Gegenständen
JP4931352B2 (ja) * 2004-01-14 2012-05-16 月桂冠株式会社 鉄補給剤及びその利用
RU2007117147A (ru) 2004-10-08 2008-11-20 Юнилевер Н.В. (Nl) Комплекс железа
US20090035385A1 (en) 2004-12-22 2009-02-05 Drugtech Corporation Compositions including iron
CN100443485C (zh) 2005-04-08 2008-12-17 吴华君 叶绿酸合铁钠盐衍生物、制备方法及用途
JP4948056B2 (ja) * 2005-09-02 2012-06-06 月桂冠株式会社 疲労の予防又は改善剤
WO2007062546A1 (fr) 2005-11-30 2007-06-07 Chongqing Pharmaceutical Research Institute Co., Ltd. Complexes fer-saccharide faciles a reconstituer et leur procede de fabrication
FR2916592B1 (fr) 2007-05-25 2017-04-14 Groupe Des Ecoles De Telecommunications(Get)-Ecole Nat Superieure Des Telecommunications(Enst) Procede de securisation d'echange d'information,dispositif, et produit programme d'ordinateur correspondant
CN101481404B (zh) 2008-12-17 2011-10-05 中国农业大学 一种酶解乳蛋白亚铁络合物微胶囊补铁剂及其制备方法

Also Published As

Publication number Publication date
JP2014509624A (ja) 2014-04-21
TWI510496B (zh) 2015-12-01
EP2691376B1 (fr) 2015-12-09
CN103429575B (zh) 2016-08-31
PT2691376E (pt) 2016-03-02
KR101889050B1 (ko) 2018-08-20
MX358194B (es) 2018-07-16
GT201300224A (es) 2015-01-20
MY168952A (en) 2019-01-28
TN2013000379A1 (en) 2015-01-20
US20140162994A1 (en) 2014-06-12
BR112013024722A2 (pt) 2016-12-20
DK2691376T3 (en) 2016-02-15
DOP2013000213A (es) 2013-11-15
AU2012234292A1 (en) 2013-10-17
BR112013024722B1 (pt) 2022-04-12
AR085736A1 (es) 2013-10-23
ZA201308050B (en) 2016-01-27
CL2013002766A1 (es) 2014-03-21
MX2013010964A (es) 2013-10-17
PE20141319A1 (es) 2014-10-29
EA201301083A1 (ru) 2014-03-31
CR20130485A (es) 2014-05-20
WO2012130882A1 (fr) 2012-10-04
EA026192B1 (ru) 2017-03-31
CN103429575A (zh) 2013-12-04
TW201245212A (en) 2012-11-16
EP2691376A1 (fr) 2014-02-05
ES2560964T3 (es) 2016-02-23
SG193981A1 (en) 2013-11-29
HUE026712T2 (en) 2016-07-28
IL228502A0 (en) 2013-12-31
ECSP13012904A (es) 2013-12-31
US9422247B2 (en) 2016-08-23
CO6811850A2 (es) 2013-12-16
IL228502A (en) 2015-02-26
AU2012234292B2 (en) 2016-09-22
CA2829240A1 (fr) 2012-10-04
NZ616045A (en) 2015-04-24
PL2691376T3 (pl) 2016-06-30
KR20140027196A (ko) 2014-03-06
CA2829240C (fr) 2016-11-22
JP5923161B2 (ja) 2016-05-24

Similar Documents

Publication Publication Date Title
MA34067B1 (fr) Composés à base de complexes de fe(iii) pour le traitement et la prévention des carences en fer et des anémies dues à une carence en fer
MA40893B1 (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
MA44851B1 (fr) Dérivés pyridinyltriazole substitués par des groupements amides et leurs utilisations
MA45153B1 (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA35601B1 (fr) Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1
CA2883210C (fr) Composes aza bicycliques utilises comme agonistes du recepteur muscarinique m1
MA41562B1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA38146B1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
MA34308B1 (fr) Triazolopyridines substituées
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
BR112015008046A2 (pt) composições biocidais que compreendem quelantes de ferro
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA41185B1 (fr) Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc
MA39927B1 (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
MA39170A1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MA20150279A1 (fr) (r)-nifuratel, son utilisation pour le traitement d'infections et synthèse de (r) et (s)-nifuratel
MA38425B1 (fr) Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1
MA34977B1 (fr) Composés à base de complexes de FE(III) pour le traitement et la prévention de carences en fer et d'anémies dues à une carence en fer.
MA34952B1 (fr) Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA37524B1 (fr) Procedes de production de chlorhydrate d'anamoreline presentant une teneur en chlorure regulee